Research programme: cancer vaccines - Dynavax Technologies

Drug Profile

Research programme: cancer vaccines - Dynavax Technologies

Alternative Names: TLR9-adjuvanted nanoparticle cancer vaccine - Dynavax Technologies

Latest Information Update: 01 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dynavax Technologies
  • Class Antigens; Antineoplastics; Oligonucleotides; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Cancer in USA (Intratumoural)
  • 01 Apr 2017 Preclinical data in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top